Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Total Current Liabilities (2021 - 2025)

Prime Medicine filings provide 5 years of Total Current Liabilities readings, the most recent being $37.4 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 1.35% to $37.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.4 million, a 1.35% decrease, with the full-year FY2025 number at $37.4 million, down 1.35% from a year prior.
  • Total Current Liabilities hit $37.4 million in Q4 2025 for Prime Medicine, up from $35.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $58.0 million in Q4 2021 to a low of $20.7 million in Q2 2024.
  • Median Total Current Liabilities over the past 5 years was $34.3 million (2025), compared with a mean of $34.5 million.
  • Biggest five-year swings in Total Current Liabilities: crashed 53.93% in 2022 and later soared 111.21% in 2023.
  • Prime Medicine's Total Current Liabilities stood at $58.0 million in 2021, then crashed by 53.93% to $26.7 million in 2022, then soared by 111.21% to $56.4 million in 2023, then plummeted by 32.72% to $38.0 million in 2024, then fell by 1.35% to $37.4 million in 2025.
  • The last three reported values for Total Current Liabilities were $37.4 million (Q4 2025), $35.0 million (Q3 2025), and $34.1 million (Q2 2025) per Business Quant data.